PMID- 35422683
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1662-4548 (Print)
IS  - 1662-453X (Electronic)
IS  - 1662-453X (Linking)
VI  - 16
DP  - 2022
TI  - The Role of Leaky Gut in Functional Dyspepsia.
PG  - 851012
LID - 10.3389/fnins.2022.851012 [doi]
LID - 851012
AB  - Patients with functional dyspepsia (FD) complain of epigastric symptoms with no 
      identifiable cause. Increased intestinal permeability has been described in these 
      patients, especially in the proximal small bowel or duodenum, and was associated 
      with mucosal immune activation and symptoms. In this review, we discuss duodenal 
      barrier function, including techniques currently applied in FD research. We 
      summarize the available data on duodenal permeability in FD and factors 
      associated to increased permeability, including mucosal eosinophils, mast cells, 
      luminal and systemic factors. While the increased influx of antigens into the 
      duodenal mucosa could result in local immune activation, clinical evidence for a 
      causal role of permeability is lacking in the absence of specific 
      barrier-protective treatments. As both existing and novel treatments, including 
      proton pump inhibitors (PPI) and pre- or probiotics may impact duodenal barrier 
      function, it is important to recognize and study these alterations to improve the 
      knowledge and management of FD.
CI  - Copyright (c) 2022 Wauters, Ceulemans, Schol, Farre, Tack and Vanuytsel.
FAU - Wauters, Lucas
AU  - Wauters L
AD  - Department of Gastroenterology and Hepatology, University Hospitals Leuven, 
      Leuven, Belgium.
AD  - Translational Research Center for Gastrointestinal Disorders (TARGID), Department 
      of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
FAU - Ceulemans, Matthias
AU  - Ceulemans M
AD  - Translational Research Center for Gastrointestinal Disorders (TARGID), Department 
      of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
FAU - Schol, Jolien
AU  - Schol J
AD  - Department of Gastroenterology and Hepatology, University Hospitals Leuven, 
      Leuven, Belgium.
AD  - Translational Research Center for Gastrointestinal Disorders (TARGID), Department 
      of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
FAU - Farre, Ricard
AU  - Farre R
AD  - Translational Research Center for Gastrointestinal Disorders (TARGID), Department 
      of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
FAU - Tack, Jan
AU  - Tack J
AD  - Department of Gastroenterology and Hepatology, University Hospitals Leuven, 
      Leuven, Belgium.
AD  - Translational Research Center for Gastrointestinal Disorders (TARGID), Department 
      of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
FAU - Vanuytsel, Tim
AU  - Vanuytsel T
AD  - Department of Gastroenterology and Hepatology, University Hospitals Leuven, 
      Leuven, Belgium.
AD  - Translational Research Center for Gastrointestinal Disorders (TARGID), Department 
      of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220329
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC9002356
OTO - NOTNLM
OT  - duodenum
OT  - functional dyspepsia
OT  - gut-brain-axis
OT  - immunology
OT  - permeability
COIS- LW reports financial support for research from Danone and MyHealth; has served on 
      the advisory board of Naturex; has served on the Speaker bureau for Dr. Falk 
      Pharma, Takeda and MyHealth. TV reports financial support for research from 
      Danone, MyHealth, Takeda and VectivBio; has served on the Speaker bureau for 
      Abbott, Dr. Falk Pharma, Fresenius Kabi, Menarini, Remedus, Takeda, Truvion, and 
      VectivBio; reports consultancy fees from Baxter, Dr. Falk Pharma, Takeda, 
      VectivBio, and Zealand Pharma. JT has given Scientific advice to Adare, 
      AlfaWassermann, Arena, Bayer, Christian Hansen, Clasado, Danone, Devintec, Falk, 
      FitForMe, Grunenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, 
      Neurogastrx, Neutec, Novartis, Nutricia, Reckitt Benckiser, Ricordati, Shionogi, 
      Takeda, Truvion, Tsumura, Zealand, and Zeria pharmaceuticals, has received 
      research support from Biohit, Shire, Sofar, and Takeda, and has served on the 
      Speaker bureau for Abbott, Allergan, AstraZeneca, FitForMe, Janssen, Kyowa Kirin, 
      Mayoly, Menarini, Mylan, Novartis, Schwabe Parmaceuticals, Takeda, Wellspect, and 
      Zeria. All the fundings reported were outside of this study. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2022/04/16 06:00
MHDA- 2022/04/16 06:01
PMCR- 2022/01/01
CRDT- 2022/04/15 05:24
PHST- 2022/01/08 00:00 [received]
PHST- 2022/03/07 00:00 [accepted]
PHST- 2022/04/15 05:24 [entrez]
PHST- 2022/04/16 06:00 [pubmed]
PHST- 2022/04/16 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fnins.2022.851012 [doi]
PST - epublish
SO  - Front Neurosci. 2022 Mar 29;16:851012. doi: 10.3389/fnins.2022.851012. 
      eCollection 2022.